* Note: Prices are in Million (M) USD.
Description:
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. The company is headquartered in Irvine, California.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $30 M
Debt : $7 M
EBITDA : $-39 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Health Care
Industry: Medical Devices
Based on industry, 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Average Free Cash Flow: $-48 M
Average Revenue: $26 M
Revenue Converted To Free Cash Flow (%): -188%
Avg Free Cash Flow Growth Per Year (Last 2 Years): -5.58%
Since Free Cash Flow (FCF) to Revenue percentage is non-positive, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Error: This stock does not have 5 years of revenue data.Using default values for calculation.
Based on default values, 1 points assigned.
This criteria used Company's ability to buy back its own share:
Error: This stock does not have 5 years of share count data.Using default values for calculation.
Based on default values, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Message: Cannot calculate payout ratio because EPS is either 0 or negative.
Using default values for calculation.
Based on default values, 1 points assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Average ROE: -215%
Since Average ROE is negative, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $16
52-Week Low: $9
Threshold Price (15% Above 52-Week Low): $10
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $945 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 1% exposure of Total Portfolio.
Value-Trade has assigned 7 points to above Beta Bionics, Inc. Common Stock (BBNX) stock.
The fair value of Beta Bionics, Inc. Common Stock (BBNX) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
